Familial clustering of site-specific cancer risks associated with BRCA1 and BRCA2 mutations in the Ashkenazi Jewish population
Sharon Simchoni(Shaare Zedek Medical Center), Ephrat Levy‐Lahad(Hebrew University of Jerusalem), Eitan Friedman(University of Pennsylvania), Raphael Catane(Tel Aviv University), Amnon Lahad(Hebrew University of Jerusalem), Mary‐Claire King(University of Washington), Bella Kaufman(NYU Langone Health), Sigal Tsabari(Tel Aviv Sourasky Medical Center), Ruth Gershoni‐Baruch(Technion – Israel Institute of Technology), Inbal Kedar‐Barnes(Rabin Medical Center), Ronit Shiri‐Sverdlov(Maastricht University), Efrat Dagan(University of Haifa), Mordechai Shohat(Rafael Advanced Defense Systems (Israel)), Avi Orr‐Urtreger(Texas Medical Center)
Cited by 89
Related Papers
Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
|New England Journal of Medicine|2009|2.1k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
|Annals of Oncology|2020|1.4k
4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
|Annals of Oncology|2018|1.2k